T1	p 93 130	advanced epithelial ovarian carcinoma
T2	p 296 392	patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen
T3	p 416 464	Patients with bidimensionally measurable disease
T4	p 980 1003	A total of 226 patients
T5	p 1933 1958	relapse of ovarian cancer
T6	i 62 71	topotecan
T7	i 79 89	paclitaxel
T8	i 265 274	topotecan
T9	i 282 292	paclitaxel
T10	i 484 493	topotecan
T11	i 532 542	paclitaxel
T12	i 1162 1171	topotecan
T13	i 1279 1289	paclitaxel
T14	i 1420 1429	topotecan
T15	i 1509 1519	paclitaxel
T16	i 1605 1614	Topotecan
T17	i 1676 1686	paclitaxel
T18	i 1920 1929	topotecan
T19	o 685 792	European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire
T20	o 870 967	pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia
T21	o 1195 1206	progression
T22	o 1397 1412	median survival
T23	o 1651 1659	efficacy
T24	o 1664 1672	survival
T25	o 1722 1745	haematological toxicity
T26	o 1748 1775	Non-haematological toxicity